RANK, RANKL, and OPG in recurrent solid/multicystic ameloblastoma: Their distribution patterns and biologic significance

Chong Huat Siar, Hidetsugu Tsujigiwa, Ismadi Ishak, Nurmawarnis Mat Hussin, Hitoshi Nagatsuka, Kok Han Ng

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives To determine the distribution patterns of bone resorption regulators, receptor activator of nuclear factor κ-B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) in recurrent ameloblastoma (RAs) and to clarify their impact on the biologic behavior of these neoplasms.

Materials and Methods Fifteen paraffin-embedded RA cases were subjected to immunohistochemistry for expression of RANK, RANKL, and OPG.

Results The RANK-RANKL-OPG triad was heterogeneously detected in RA samples. RANK, essential for osteoclast differentiation, was strongly expressed in tumoral epithelium. Conversely, RANKL, an osteoclast activator, was markedly underexpressed, and protein localization was predominantly stromal. OPG, an osteoclastogenesis inhibitory factor, was detected in neoplastic epithelium more than in stroma, suggesting functional inactivation of RANKL. Most RA (n = 12/15; 80%) exhibited a bimolecular spatial expression pattern, the most common being RANK-positive/OPG-positive (n = 8/15; 53.3%). All three proteins showed no significant correlation with the clinical/histopathologic parameters in RA patients (P >.05).

Conclusions The RANK+/RANKLlow/-/OPG+ phenotype observed in RA suggests an altered local bone metabolism characterized by low bone resorptive activity in these recurrent tumors.

Original languageEnglish
Pages (from-to)83-91
Number of pages9
JournalOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Volume119
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

RANK Ligand
Ameloblastoma
Osteoprotegerin
Osteoclasts
Epithelium
Bone and Bones
Bone Resorption
Cytoplasmic and Nuclear Receptors
Paraffin
Neoplasms
Proteins
Immunohistochemistry
Phenotype

ASJC Scopus subject areas

  • Surgery
  • Oral Surgery
  • Pathology and Forensic Medicine
  • Radiology Nuclear Medicine and imaging
  • Dentistry (miscellaneous)

Cite this

RANK, RANKL, and OPG in recurrent solid/multicystic ameloblastoma : Their distribution patterns and biologic significance. / Siar, Chong Huat; Tsujigiwa, Hidetsugu; Ishak, Ismadi; Hussin, Nurmawarnis Mat; Nagatsuka, Hitoshi; Ng, Kok Han.

In: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, Vol. 119, No. 1, 01.01.2015, p. 83-91.

Research output: Contribution to journalArticle

Siar, Chong Huat ; Tsujigiwa, Hidetsugu ; Ishak, Ismadi ; Hussin, Nurmawarnis Mat ; Nagatsuka, Hitoshi ; Ng, Kok Han. / RANK, RANKL, and OPG in recurrent solid/multicystic ameloblastoma : Their distribution patterns and biologic significance. In: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2015 ; Vol. 119, No. 1. pp. 83-91.
@article{4572903b58164aeb8f8d638988a23d3e,
title = "RANK, RANKL, and OPG in recurrent solid/multicystic ameloblastoma: Their distribution patterns and biologic significance",
abstract = "Objectives To determine the distribution patterns of bone resorption regulators, receptor activator of nuclear factor κ-B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) in recurrent ameloblastoma (RAs) and to clarify their impact on the biologic behavior of these neoplasms.Materials and Methods Fifteen paraffin-embedded RA cases were subjected to immunohistochemistry for expression of RANK, RANKL, and OPG.Results The RANK-RANKL-OPG triad was heterogeneously detected in RA samples. RANK, essential for osteoclast differentiation, was strongly expressed in tumoral epithelium. Conversely, RANKL, an osteoclast activator, was markedly underexpressed, and protein localization was predominantly stromal. OPG, an osteoclastogenesis inhibitory factor, was detected in neoplastic epithelium more than in stroma, suggesting functional inactivation of RANKL. Most RA (n = 12/15; 80{\%}) exhibited a bimolecular spatial expression pattern, the most common being RANK-positive/OPG-positive (n = 8/15; 53.3{\%}). All three proteins showed no significant correlation with the clinical/histopathologic parameters in RA patients (P >.05).Conclusions The RANK+/RANKLlow/-/OPG+ phenotype observed in RA suggests an altered local bone metabolism characterized by low bone resorptive activity in these recurrent tumors.",
author = "Siar, {Chong Huat} and Hidetsugu Tsujigiwa and Ismadi Ishak and Hussin, {Nurmawarnis Mat} and Hitoshi Nagatsuka and Ng, {Kok Han}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.oooo.2014.09.017",
language = "English",
volume = "119",
pages = "83--91",
journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",
issn = "2212-4403",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - RANK, RANKL, and OPG in recurrent solid/multicystic ameloblastoma

T2 - Their distribution patterns and biologic significance

AU - Siar, Chong Huat

AU - Tsujigiwa, Hidetsugu

AU - Ishak, Ismadi

AU - Hussin, Nurmawarnis Mat

AU - Nagatsuka, Hitoshi

AU - Ng, Kok Han

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives To determine the distribution patterns of bone resorption regulators, receptor activator of nuclear factor κ-B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) in recurrent ameloblastoma (RAs) and to clarify their impact on the biologic behavior of these neoplasms.Materials and Methods Fifteen paraffin-embedded RA cases were subjected to immunohistochemistry for expression of RANK, RANKL, and OPG.Results The RANK-RANKL-OPG triad was heterogeneously detected in RA samples. RANK, essential for osteoclast differentiation, was strongly expressed in tumoral epithelium. Conversely, RANKL, an osteoclast activator, was markedly underexpressed, and protein localization was predominantly stromal. OPG, an osteoclastogenesis inhibitory factor, was detected in neoplastic epithelium more than in stroma, suggesting functional inactivation of RANKL. Most RA (n = 12/15; 80%) exhibited a bimolecular spatial expression pattern, the most common being RANK-positive/OPG-positive (n = 8/15; 53.3%). All three proteins showed no significant correlation with the clinical/histopathologic parameters in RA patients (P >.05).Conclusions The RANK+/RANKLlow/-/OPG+ phenotype observed in RA suggests an altered local bone metabolism characterized by low bone resorptive activity in these recurrent tumors.

AB - Objectives To determine the distribution patterns of bone resorption regulators, receptor activator of nuclear factor κ-B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) in recurrent ameloblastoma (RAs) and to clarify their impact on the biologic behavior of these neoplasms.Materials and Methods Fifteen paraffin-embedded RA cases were subjected to immunohistochemistry for expression of RANK, RANKL, and OPG.Results The RANK-RANKL-OPG triad was heterogeneously detected in RA samples. RANK, essential for osteoclast differentiation, was strongly expressed in tumoral epithelium. Conversely, RANKL, an osteoclast activator, was markedly underexpressed, and protein localization was predominantly stromal. OPG, an osteoclastogenesis inhibitory factor, was detected in neoplastic epithelium more than in stroma, suggesting functional inactivation of RANKL. Most RA (n = 12/15; 80%) exhibited a bimolecular spatial expression pattern, the most common being RANK-positive/OPG-positive (n = 8/15; 53.3%). All three proteins showed no significant correlation with the clinical/histopathologic parameters in RA patients (P >.05).Conclusions The RANK+/RANKLlow/-/OPG+ phenotype observed in RA suggests an altered local bone metabolism characterized by low bone resorptive activity in these recurrent tumors.

UR - http://www.scopus.com/inward/record.url?scp=84915822030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915822030&partnerID=8YFLogxK

U2 - 10.1016/j.oooo.2014.09.017

DO - 10.1016/j.oooo.2014.09.017

M3 - Article

C2 - 25446507

AN - SCOPUS:84915822030

VL - 119

SP - 83

EP - 91

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

SN - 2212-4403

IS - 1

ER -